Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms SALV-ENZA

Most Recent Events

30 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
20 Jan 2023 Planned End Date changed from 10 Jan 2023 to 1 Dec 2023.
11 Nov 2022 Results assessing efficacy and safety of salvage radiation therapy plus enzalutamide in men with recurrent prostate cancer after radical prostatectomy, published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight